Please assess the completion status of the following clinical trial:

Trial Title: Safety of the Etonogestrel-releasing Implant During the Puerperium of Healthy Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age between 18 and 35 years~* Postpartum contraception desire~Exclusion Criteria:~* smoking, alcoholism or drug addiction~* presence of systemic diseases (diabetis melittus, cardiovascular disease, autoimmune diseases, liver disease, thyroid disease, or congenital renal hyperplasia)~* having a body mass index ≥ 30 kg/m2~* personal history of arterial or venous thrombosis~* using any medication that might interfere with blood coagulation or with the assessment of haemostatic and inflammatory variables~* presenting alterations in hepatic enzymes~* being allergic to local anaesthetics (xylocaine)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: t

Study Arms:
- etonogestrel implant (Type: EXPERIMENTAL): Etonogestrel releasing contraceptive implant (Implanon®, NV Organon, Oss, The Netherlands) inserted 24-48 h after delivery. It is compounded by 68mg of etonogestrel, 3years of duration.
- depot medroxyprogesterone acetate (Type: ACTIVE_COMPARATOR): At the 6th week postpartum, this group received intramuscular 150 mg of depot medroxyprogesterone acetate (Contracept®, EMS Sigma Pharma, Hortolandia, Brazil).

Based on this trial design, predict the completion outcome and termination type (if applicable).